US Broker Ratings

Palvella Therapeutics, Inc. (PVLA): Investor Outlook and 78.86% Potential Upside in Biotech Breakthroughs

Palvella Therapeutics, Inc. (NASDAQ: PVLA) is catching the eye of investors with its promising pipeline in the biotechnology sector, particularly in the niche of rare genetic skin diseases. Based in..

AppFolio, Inc. (APPF) Stock Analysis: Unveiling a 70% Upside Potential

AppFolio, Inc. (NASDAQ: APPF), a key player in the Software – Application industry, has been making waves with its innovative cloud-based solutions tailored for the real estate sector. With a..

Abeona Therapeutics Inc. (ABEO) Stock Analysis: Exploring a Potential 262% Upside in Biotechnology

Abeona Therapeutics Inc. (NASDAQ: ABEO), a Cleveland-based biopharmaceutical company specializing in gene and cell therapies, is capturing investor attention with its promising pipeline and substantial upside potential. Operating in the..

aTyr Pharma, Inc. (ATYR) Stock Analysis: Understanding the 417% Potential Upside in the Biotech Sector

aTyr Pharma, Inc. (NASDAQ: ATYR), a clinical-stage biotechnology company, is generating significant buzz among investors, thanks to its impressive 417% potential upside as indicated by analyst price targets. This San..

Senseonics Holdings, Inc. (SENS): Growth Potential and Analyst Consensus Indicate 174% Upside

Senseonics Holdings, Inc. (NYSE: SENS) is drawing attention from investors with its promising growth trajectory in the healthcare sector. The company, a frontrunner in the medical devices industry, specializes in..

Viemed Healthcare, Inc. (VMD) Stock Analysis: Exploring a 35% Potential Upside

Viemed Healthcare, Inc. (NASDAQ: VMD) has emerged as a noteworthy player in the healthcare sector, particularly within the medical devices industry, by offering innovative home medical equipment and post-acute respiratory..

Mereo BioPharma Group plc (MREO) Stock Analysis: Exploring a Potential 423% Upside in the Biotech Sector

Investors interested in the dynamic world of biotechnology should take a closer look at Mereo BioPharma Group plc (NASDAQ: MREO), a UK-based biopharmaceutical company making strides in developing treatments for..

CytomX Therapeutics, Inc. (CTMX) Stock Analysis: Exploring a 199.71% Potential Upside in the Biotech Innovator

CytomX Therapeutics, Inc. (CTMX), a U.S.-based biotechnology company specializing in oncology-focused biopharmaceuticals, is garnering significant attention from investors due to its innovative approach and substantial growth potential. With a market..

Nyxoah SA (NYXH) Stock Analysis: Exploring a 208% Potential Upside in the Medical Tech Sector

Nyxoah SA (NYSE: NYXH), a trailblazer in the healthcare sector, is gaining investor attention with a staggering potential upside of approximately 208.72%. This Belgian medical technology company specializes in developing..

Sprout Social, Inc. (SPT) Stock Analysis: Evaluating the 79.53% Potential Upside for Investors

Sprout Social, Inc. (NASDAQ: SPT), a prominent player in the technology sector, specializes in software applications that streamline social media management across various industries. Operating from Chicago, Illinois, Sprout Social..

Aurora Cannabis Inc. (ACB)

⚠️ No article content returned.

..

Neurogene Inc. (NGNE) Stock Analysis: Exploring a 223% Potential Upside in the Biotechnology Sector

Neurogene Inc. (NASDAQ: NGNE), a promising player in the biotechnology sector, has been capturing the attention of investors with its focus on developing genetic medicines for rare neurological diseases. The..

A2Z Cust2Mate Solutions Corp. (AZ) Stock Analysis: Unpacking the 161% Potential Upside

A2Z Cust2Mate Solutions Corp. (AZ), a Canadian technology company, has recently captured investor attention with its innovative solutions and promising growth potential. Specializing in smart cart solutions for the retail..

Lyft, Inc. (LYFT) Stock Analysis: Evaluating a 31% Potential Upside with Robust Free Cash Flow

Lyft, Inc. (NASDAQ: LYFT), a prominent player in the Technology sector’s Software – Application industry, has captured investor attention with its compelling 31.53% potential upside. As the company continues to..

Entrada Therapeutics, Inc. (TRDA) Stock Analysis: Exploring a Potential 52.97% Upside in the Biotech Sector

Investors with a keen eye on the biotechnology landscape may find Entrada Therapeutics, Inc. (NASDAQ: TRDA) an intriguing prospect. With its focus on developing innovative treatments for neuromuscular and inherited..

Spok Holdings, Inc. (SPOK) Investor Outlook: Evaluating a High Dividend Yield and Potential Upside

Spok Holdings, Inc. (NASDAQ: SPOK), a key player in the Health Information Services industry, stands out for its distinctive value proposition in the healthcare sector. With a market capitalization of..

Asana, Inc. (ASAN) Stock Analysis: Eyeing a 62.9% Potential Upside Amidst Software Sector Challenges

Asana, Inc. (NYSE: ASAN), a prominent player in the software application industry, presents an intriguing opportunity for investors, particularly those looking at the technology sector’s potential for substantial returns. With..

Chevron Corporation (CVX) Stock Analysis: A Deep Dive into Its 14% Upside Potential

Chevron Corporation (NYSE: CVX), a titan in the energy sector, continues to capture investor attention with its extensive global operations and a promising potential upside of 14.22%. With a market..

CS Disco, Inc. (LAW) Stock Analysis: Potential Upside of Nearly 58% Makes It a Legal Tech Contender

For investors seeking opportunities in the dynamic intersection of technology and law, CS Disco, Inc. (NASDAQ: LAW) presents an intriguing proposition. Specializing in cloud-native and AI-powered legal products, CS Disco..

Vanda Pharmaceuticals Inc. (VNDA) Stock Analysis: Exploring the 113% Potential Upside

Vanda Pharmaceuticals Inc. (NASDAQ: VNDA), a biopharmaceutical company based in Washington, D.C., is making headlines with its promising growth potential. Specializing in therapies targeting high unmet medical needs, Vanda’s stock..

Search

Funds

US Broker Ratings

Search

Funds

US Broker Ratings

FTSE 100

Funds